OM99-2 (TFA)

OC([C@H](CC1=CC=CC=C1)NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](C)C[C@H](O)[C@H](CC(C)C)NC([C@H](CC(N)=O)NC([C@H](C(C)C)NC([C@@H](N)CCC(O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O

[1]Ghosh AK, et al. Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase) . J Am Chem Soc. 2000;122 (14) :3522-3523.|[2]Zhao J, et al. Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. Front Mol Neurosci. 2020;13:137. Published 2020 Aug 4.|[3]Dash C, et al. Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol. 2003;38 (2) :89-119.|[4]Park H, et al. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J Am Chem Soc. 2003;125 (52) :16416-16422.